Ahead of World Digestive Health 2022, Italian pharmaceutical group Alfasigma is proud to announce the launch of its new diagnostic drug Lumeblue™ (per-oral methylene blue). This latest innovation is part of the company’s commitment to raising awareness on colorectal cancer (CRC), still the second leading cause of cancer deaths worldwide, through a healthy lifestyle and regular screenings.
#LeaveYourMark is back. #LeaveYourMark 2022 goes international sharing thoughts and experiences of Alfasigma colleagues from all over the world online.
Jean-Christophe Lemaistre, before joining Alfasigma France, has covered different managerial roles
Gastrointestinal therapeutics are our specialty. Everyday we strive to give a concrete answer to functional gastro-intestinal disorders, gastro-oesophageal reflux disorder, hepatic encephalopathy and chronic liver disease (cirrhosis).
Vascular investigation is a company corporate mission. Venous diseases, lower extremity artery disease, diabetic microangiopathies and ventricular arrhythmia are the main pathologies in which we offer solutions.
In the metabolic area, our R&D has developed Carnitine, an amino acid derivative whose insufficiency can impair the metabolism of essential tissues, such as those of the heart and muscles.
With our supplements, we are responding to the demand for a vast range of elements aimed at neural tissue well-being, recovery of muscle tone and combating physical and mental fatigue.
doctorAsyou provides physicians and researchers with easier and smarter access to the most relevant EBM (Evidence Based Medicine) topics.
The doctorAsyou search engine is updated daily and returns over 30 million abstracts, combining the three most authoritative databases in the world: Pubmed, ICRTP, Clinicaltrials.gov
lf you're searching for a scientific article, a paper, an abstract or more, try to use it directly from this search bar.
You’re entering Alfasigma global website
I agree